Sequencing symptom control: Results from the Alliance N08C1 and N08CA genetics of chemotherapy neuropathy trials Beutler, A. S. , Kulkarni, A. , Kanwar, R. , Qin, R. ... - AACR - AACR 2013 Annual Meeting - 2013 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Symptom Inter - N08C1 , N08CA
Heritable polymorphism predisposes to high expression of BAALC in cytogenetically normal acute myeloid leukemia (CN-AML) Eisfeld, Ann-Kathrin , Marcucci, G. , Liyanarachchi, S. , Döhner, K. ... - AACR - AACR Annual Meeting - 2012 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C9665
Z1031B neoadjuvant aromatase inhibitor trial: A Phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level >10% Ellis, M. J. , Suman, V , McCall, L. , Luo, R. , Hoog, J. , Brink, A. ... - AACR - Cancer Res. - 2012 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031B
Body mass index, weight loss, and progression and mortality in metastatic colorectal cancer (Alliance) Guercio, Brendan J. , Zhang, Sui , Venook, Alan P. , Ou, Fang-Shu ... - AACR - - 2019 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405
A comparison of two methodologies to quantify Thymidylate synthase for predicting survival in patients with colorectal cancer treated on CALGB 89803 Hasson, R. M. , Niedzwiecki, D. ... - AACR - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
Genetic prediction of VEGF-A plasma levels in cancer patients CALGB 80303 (Alliance) Innocenti, Federico , Jiang, Chen , Sibley, Alexander ... - AACR - Cancer Res - 2016 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-80303
Utility of circulating biomarkers as outcome predictors in metastatic colorectal cancer and recurrent glioblastoma multiforme patients treated with bevacizumab/sorafenib Lafky, J. M. , Anderson, S. K. , Morlan, B. W. , Nelson, G. D. ... - AACR - Cancer Res. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N054C
Genetic variant associations with treatment outcome and safety in metastatic colorectal cancer patients treated with sorafenib and bevacizumab (BEV) as salvage therapy Lafky, J. , Bot, B. , Morlan, B. ... - AACR - Proc Am Assoc Can Res - 2011 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N054C
PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy Liu, M. , Pitcher, B. , Mardis, E. , Davies, S. , Snider, J. ... - AACR - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-9741
High ERG expression levels predict adverse outcome and refine molecular risk-based classification of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study Marcucci, G. , Maharry, K. S. , Whitman, S. P. , Vukosavljevic, T. ... - AACR - AACR Annual Meeting - 2007 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
N0937 (Alliance): Preliminary results of a phase II clinical trial of cisplatin and the novel agent brostallicin in patients with metastatic triple negative breast cancer (mTNBC) Moreno-Aspitia, A. , Rowland, K. M. Jr , Allred, J. B. , Liu, H. ... - AACR - Cancer Res. - 2012 Abstract - Primary Endpoint - Preliminary Analysis - Breast - N0937
FTY720, a new and alternative strategy for treating blast crisis CML and Ph1 ALL patients Neviani, P. , Santhanam, R. , Oaks, J. , Eiring, A. , Notari, M. ... - AACR - AACR Annual Meeting - 2007 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-8461 , CALGB-9665
A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance) Patel, Jai N. , Jiang, Chen , Owzar, Kouros , Hertz, Daniel L. ... - AACR - Cancer Res. - 2016 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-90401
Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study Perez, E. , Eckel-Passow, J. , Ballman, K. , Anderson, S. ... - AACR - Cancer Res. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831
Higher MN1 expression is an unfavorable prognosticator in older patients (Pts) with cytogenetically normal acute myeloid leukemia (CN-AML): A CALGB study Schwind, S. , Marcucci, G. , Holland, K. B. , Mrózek, K. ... - AACR - AACR Annual Meeting - 2010 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C20502 , C9665 , C8461 , C9621 , C19808
A randomized phase II trial of vitamin D vs placebo in premenopausal women: CALGB 70806 Wood, M. E. , Kinglsey, F. , Ambaye, A. B. , Yee, L. , Jung, S. J. ... - AACR - Cancer Res. - 2011 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Prevention - CALGB-70806
